At least nine biotechs and pharmas are slated to report earnings this week. 4Q13 EPS is expected to decline for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) despite a 39% increase in revenues to $577.9 million. Regeneron, which markets ophthalmic drug Eylea aflibercept, reported a 40% increase in combined SG&A and R&D expenses to $839.1 million in the first nine